D Cyclins in CD5+ B-Cell Lymphoproliferative Disorders Cyclin D1 and Cyclin D2 Identify Diagnostic Groups and Cyclin D1 Correlates With ZAP-70 Expression in Chronic Lymphocytic Leukemia

Department of Pathology, Case Western Reserve University and the Ireland Cancer Center, University Hospitals of Cleveland, Cleveland, OH 44106, USA.
American Journal of Clinical Pathology (Impact Factor: 2.51). 03/2006; 125(2):241-50. DOI: 10.1309/7C2V-V961-P60R-MLHD
Source: PubMed


We analyzed protein expression of cyclin D1, cyclin D2, and cyclin D3 using high-resolution enzymatic amplification staining and flow cytometry in the neoplastic cells from 80 patients with CD5+ B-cell lymphoproliferative disorders. The D cyclins were expressed differentially in chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), and mantle cell lymphoma (MCL) with strong staining of cyclin D1 and D2 in MCL, strong staining of cyclin D1 but weak staining of cyclin D2 in 4 of 5 PLLs, and low-level staining for both cyclins in most CLLs. No correlation between cyclin D1 and D2 and growth rates or CD38 expression was observed. However, cyclin D1 levels were significantly higher in ZAP-70+ CLL cases, although no association between ZAP-70 and cyclin D2 was detected. The results indicate that flow cytometric analysis of D cyclins may help in classification of CD5+ B-cell lymphoproliferative disorders.

Download full-text


Available from: David Kaplan, Mar 24, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ZAP-70 protein expression has been proposed as a marker for immunoglobulin heavy chain mutational status, which some studies have correlated with disease course in B-cell chronic lymphocytic leukemia (CLL). Studies published to date measuring levels of expression of ZAP-70 intracellular protein using flow cytometry have demonstrated poor performance, as defined by the difference in signal in known positive and negative lymphocyte populations. A recently published method (Chow S, Hedley DW, Grom P, Magari R, Jacobberger JW, Shankey TV, Cytometry A 2005;67:4-17) to measure intracellular phospho-epitopes was optimized using a design of experiments (DOE) approach to provide the best separation of ZAP-70 expression in positive T- or NK-cells as compared to negative B-cells in peripheral blood samples. A number of commercially available anti-ZAP-70 antibody-conjugates were screened using this methodology, and the antibody-conjugate showing the best performance was chosen to develop a four-color, five antibody assays to measure ZAP-70 levels in whole blood specimens. Using the optimized fixation and permeabilization method, improvement in assay performance (signal-to-noise, S/N) was seen in most of the antibodies tested. The custom SBZAP conjugate gave the best S/N when used in conjunction with this optimized fixation /permeabilization method. In conjunction with carefully standardized instrument set-up protocols, we obtained both intra- and interlaboratory reproducibility in the analysis of ZAP-70 expression in whole blood samples from normal and CLL patients. The development of a sensitive, specific and highly reproducible ZAP-70 assay represents only the first essential step for any clinical assay. The universal implementation of a validated data analysis method and the establishment of methodology-based cutoff points for clinical outcomes must next be established before ZAP-70 protein analysis can be routinely implemented in the clinical laboratory.
    Cytometry Part B Clinical Cytometry 07/2006; 70(4):259-69. DOI:10.1002/cyto.b.20135 · 2.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic lymphocytic leukemia (CLL) is characterized by a clonal expansion of small lymphocytes commonly expressing cell surface markers (CD5 and CD19) that are consistent with a population of B lymphocytes. This unit describes a technique to measure ZAP-70 protein expression in whole-blood specimens from CLL samples. The protocols presented include an optimized fixation/permeabilization technique that allows labeling of cell surface markers and intracellular ZAP-70 protein with significantly improved signal-to-noise ratio, an optimized combination of antibodies-fluorophores to maximize ZAP-70 expression levels, standardized methodology for instrument setup, including compensation, to improve inter- and intra-laboratory reproducibility, and a method to index ZAP-70 protein expression levels to internal positive and negative cell populations. Residual normal T and B cells function as internal positive and negative controls. These are used to index ZAP-70 protein expression levels in the CLL population.
    Current protocols in cytometry / editorial board, J. Paul Robinson, managing editor ... [et al.] 02/2007; Chapter 9:Unit9.22. DOI:10.1002/0471142956.cy0922s39
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evaluation of B-lymphocytes is one of the most well-established clinical applications of flow cytometric immunophenotyping. Using this technique, B-lymphocytes are recognized by expression of lineage-associated antigens; the profile of antigens expressed identifies B-cells at different stages of maturation and belonging to different biologic compartments; neoplastic B-cells can be distinguished from reactive B-cells by demonstration of immunoglobulin light chain restriction or phenotypic aberrancy; and the phenotype of the neoplastic cells can be used to identify one of the distinct disease entities recognized in the World Health Organization classification [1]. However, because of overlapping phenotypes, flow cytometric immunophenotyping is often used in conjunction with other studies as part of a multiparametric approach to the diagnosis of B-cell lymphoid neoplasms [1]. This article addresses general principles of the flow cytometric evaluation of B-cell lymphoid neoplasms, followed by discussion of how flow cytometric data can assist in determining a list of diagnostic possibilities and directing additional testing.
    Clinics in Laboratory Medicine 10/2007; 27(3):487-512, vi. DOI:10.1016/j.cll.2007.05.003 · 1.37 Impact Factor
Show more